<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396015</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00054165</org_study_id>
    <nct_id>NCT04396015</nct_id>
  </id_info>
  <brief_title>Evaluating Cognitive and Functional Impairment in Alzheimer's Dementia With a Ketogenic Diet.</brief_title>
  <official_title>Evaluating Cognitive and Functional Impairment in Alzheimer's Dementia With a Ketogenic Diet.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is being done in a scientifically rigorous manner, using readily available
      MCT oil (refined from coconut oil) versus a placebo oil to assess any cognitive and
      functional benefits for AD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study, is a randomized placebo controlled cross-over study for 6 months, with an
      open label extension for another 6 months designed to test the benefits and safety of MCT oil
      in patients with established AD. It will be the first study on MCT oil ever done with this
      design, and for this duration in AD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized, placebo control cross-over study, with an open label extension</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>cognition</measure>
    <time_frame>15months</time_frame>
    <description>Mini Mental Status Examination (MMSE). 0-30. Higher score with higher cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognition</measure>
    <time_frame>15 months</time_frame>
    <description>Montreal Cognitive Assessment (MoCA) 0-30. Higher score with higher cognition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cognition</measure>
    <time_frame>15 months</time_frame>
    <description>Cognigram (Cogstate) 0-200. Higher score with higher cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavior</measure>
    <time_frame>15 months</time_frame>
    <description>Neuropsychiatric Inventory (NPI) 0-96 Higher score with more behaviour problems</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Function</measure>
    <time_frame>15 months</time_frame>
    <description>Katz Activities of Daily Living Scale 0-6 Higher score with poorer ADL function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum tolerated daily dose (ml) of MCT oil</measure>
    <time_frame>11 months</time_frame>
    <description>tolerability of MCT oil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum tolerated daily dose (ml) of placebo (olive) oil</measure>
    <time_frame>4 months</time_frame>
    <description>tolerability of placebo oil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cholesterol mmol/l</measure>
    <time_frame>15 months</time_frame>
    <description>safety (% change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Triglyceride mmol/l</measure>
    <time_frame>15 months</time_frame>
    <description>safety (% change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Low density lipoprotein (LDL) mmol/l</measure>
    <time_frame>15 months</time_frame>
    <description>safety (% change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual Energy Absorptiometry (DXA) Body fat</measure>
    <time_frame>15 months</time_frame>
    <description>safety (% change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse events</measure>
    <time_frame>15 months</time_frame>
    <description>safety. Mild, moderate or severe events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cognitive Function 1, Social</condition>
  <arm_group>
    <arm_group_label>medium chain triglyceride (MCT) vs placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MCT or placebo (olive oil) for 4 months. Crossover at 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open label extension</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>6 months of MCT oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bulletproof Brain Octane</intervention_name>
    <description>Medium chain triglyceride oil (MCT)</description>
    <arm_group_label>medium chain triglyceride (MCT) vs placebo</arm_group_label>
    <arm_group_label>open label extension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (olive) oil</description>
    <arm_group_label>medium chain triglyceride (MCT) vs placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;49years with a clinical diagnosis of AD

          -  Mini Mental Status Examination (MMSE) score 10-29/30

          -  on stable dose of medications for 3 months (AChEI, memantine and antidepressants
             allowed)

          -  able to speak English

          -  patient or designate able to sign informed consent

          -  stable chronic medical conditions (Heart disease, thyroid disease)

          -  reliable caregiver

        Exclusion Criteria:

          -  age &lt;50 years

          -  medically unstable

          -  unable to swallow liquids

          -  diagnosis of diabetes mellitus

          -  residence in a nursing/long term care home

          -  allergy to coconut

          -  allergy to olive oil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Angela Juby</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

